Quantum Biopharma (QNTM) Long-Term Deferred Tax (2019 - 2025)

Quantum Biopharma has reported Long-Term Deferred Tax for 7 years, with the latest figure at $1.2 million in Q4 2025.

• Quarterly Long-Term Deferred Tax fell 89.69% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 89.69% YoY) and the FY2025 annual result came in at $1.2 million, down 89.69% from the prior year.
• Long-Term Deferred Tax fell to $1.2 million in Q4 2025 per QNTM's latest filing, from $10.3 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $101.9 million in Q4 2023 and troughed at $1.2 million in Q4 2025.
• A 5-year average of $44.3 million and a median of $43.6 million in 2022 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2021 and 2025: Long-Term Deferred Tax surged 106.11% in 2021, then tumbled 89.69% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $77.3 million in 2021, then gained by 16.94% to $90.4 million in 2022, then climbed by 12.7% to $101.9 million in 2023, then plunged by 88.17% to $12.1 million in 2024, then sank by 89.69% to $1.2 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $1.2 million, $10.3 million, and $12.1 million for Q4 2025, Q1 2025, and Q4 2024 respectively.